Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Neovius

Showing results (131-140 of 164) with videos related to

Pageof 17
Sort By:
The American Journal of Gastroenterology|May 22, 2024
Economic Burden of Eosinophilic Esophagitis: A Nationwide Cost-of-Illness StudySoran R Bozorg, Jonas Söderling, Karl Mårild, et al.
Rheumatology (Oxford, England)|November 12, 2020
Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquineHeather Miller, Johan K Wallman, Ingemar F Petersson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 12, 2021
Work Loss in Patients With Celiac Disease: A Population-based Longitudinal StudySoran R Bozorg, Jonas Söderling, Åsa H Everhov, et al.
Arthritis Care & Research|March 26, 2016
Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish TrialJonas K Eriksson, Johan K Wallman, Heather Miller, et al.
Annals of Surgery|January 26, 2023
Opioid Use After Gastric Bypass, Sleeve Gastrectomy or Intensive Lifestyle InterventionStefan Wallén, Gustaf Bruze, Johan Ottosson, et al.
Gastroenterology|October 21, 2018
Increased Mortality of Patients With Childhood-Onset Inflammatory Bowel Diseases, Compared With the General PopulationOla Olén, Johan Askling, Michael C Sachs, et al.
Annals of the Rheumatic Diseases|April 17, 2014
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trialJonas K Eriksson, Johan A Karlsson, Johan Bratt, et al.
The American Journal of Gastroenterology|April 30, 2020
Costs and Use of Health Care in Patients With Celiac Disease: A Population-Based Longitudinal StudyKarl Mårild, Jonas Söderling, Soran R Bozorg, et al.
Annals of the Rheumatic Diseases|December 1, 2012
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trialJohan A Karlsson, Martin Neovius, Jan-Åke Nilsson, et al.
JAMA Surgery|March 29, 2018
Associations of Bariatric Surgery With Changes in Interpersonal Relationship Status: Results From 2 Swedish Cohort StudiesGustaf Bruze, Tobias E Holmin, Markku Peltonen, et al.
Pageof 17

Showing results (131-140 of 164) with videos related to

Sort By:
Pageof 17
The American Journal of Gastroenterology|May 22, 2024
Economic Burden of Eosinophilic Esophagitis: A Nationwide Cost-of-Illness StudySoran R Bozorg, Jonas Söderling, Karl Mårild, et al.
Rheumatology (Oxford, England)|November 12, 2020
Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquineHeather Miller, Johan K Wallman, Ingemar F Petersson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 12, 2021
Work Loss in Patients With Celiac Disease: A Population-based Longitudinal StudySoran R Bozorg, Jonas Söderling, Åsa H Everhov, et al.
Arthritis Care & Research|March 26, 2016
Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish TrialJonas K Eriksson, Johan K Wallman, Heather Miller, et al.
Annals of Surgery|January 26, 2023
Opioid Use After Gastric Bypass, Sleeve Gastrectomy or Intensive Lifestyle InterventionStefan Wallén, Gustaf Bruze, Johan Ottosson, et al.
Gastroenterology|October 21, 2018
Increased Mortality of Patients With Childhood-Onset Inflammatory Bowel Diseases, Compared With the General PopulationOla Olén, Johan Askling, Michael C Sachs, et al.
Annals of the Rheumatic Diseases|April 17, 2014
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trialJonas K Eriksson, Johan A Karlsson, Johan Bratt, et al.
The American Journal of Gastroenterology|April 30, 2020
Costs and Use of Health Care in Patients With Celiac Disease: A Population-Based Longitudinal StudyKarl Mårild, Jonas Söderling, Soran R Bozorg, et al.
Annals of the Rheumatic Diseases|December 1, 2012
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trialJohan A Karlsson, Martin Neovius, Jan-Åke Nilsson, et al.
JAMA Surgery|March 29, 2018
Associations of Bariatric Surgery With Changes in Interpersonal Relationship Status: Results From 2 Swedish Cohort StudiesGustaf Bruze, Tobias E Holmin, Markku Peltonen, et al.
Pageof 17